End-of-day quote
Taipei Exchange
23:00:00 27/05/2024 BST
5-day change
1st Jan Change
92.3
TWD
+0.65%
-2.94%
-12.51%
PharmaEngine : to attend Cathay Securities Investor Conference hosted by Cathay Securities
April 28, 2022 at 08:05 am
Provided by: PharmaEngine, Inc.
SEQ_NO
2
Date of announcement
2022/04/28
Time of announcement
15:01:32
Subject
PharmaEngine Inc. to attend Cathay Securities
Investor Conference hosted by Cathay Securities
Date of events
2022/05/03
To which item it meets
paragraph 12
Statement
1.Date of institutional investor conference:2022/05/03
2.Time of institutional investor conference:14:00
3.Location of institutional investor conference:Live streaming
4.Outline of institutional investor conference:
Announcement of 1Q22 financial status and the FY22 outlook.
5.Any other matters that need to be specified:None.
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 28 April 2022 07:04:01 UTC .
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-02
CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors
04-24
CI
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC
03-18
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-12
CI
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023
02-29
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-06
CI
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers
22/09/23
CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers
15/08/23
CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
04/08/23
CI
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023
27/07/23
CI
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application
11/07/23
CI
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA
21/06/23
CI
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA
14/06/23
CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
04/05/23
CI
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales
27/04/23
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
17/03/23
CI
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07
03/03/23
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
04/11/22
CI
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson
01/09/22
CI
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022
30/08/22
CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
03/08/22
CI
Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022
26/07/22
CI
Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee
27/05/22
CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
06/05/22
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
18/03/22
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
More about the company
Last Close Price
92.3
TWD
Average target price
106
TWD
Spread / Average Target
+14.84%
Consensus
1st Jan change
Capi.
-12.51% 412M +54.05% 58.71B -2.02% 41.31B +36.98% 39.2B -10.22% 27.4B +13.42% 26.55B -21.60% 18.98B +2.89% 12.51B +22.40% 11.94B +27.49% 12.08B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1